

# Sarah Ringold

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1753750/publications.pdf>

Version: 2024-02-01

55  
papers

2,979  
citations

236925

25  
h-index

175258

52  
g-index

56  
all docs

56  
docs citations

56  
times ranked

2711  
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinctions Between Diagnostic and Classification Criteria?. Arthritis Care and Research, 2015, 67, 891-897.	3.4	386
2	Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis and Rheumatism, 2012, 64, 2012-2021.	6.7	259
3	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Entesitis. Arthritis Care and Research, 2019, 71, 717-734.	3.4	225
4	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis and Rheumatism, 2013, 65, 2499-2512.	6.7	211
5	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis Care and Research, 2013, 65, 1551-1563.	3.4	211
6	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care and Research, 2019, 71, 703-716.	3.4	176
7	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. The Lancet Child and Adolescent Health, 2019, 3, 255-263.	5.6	120
8	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Entesitis. Arthritis and Rheumatology, 2019, 71, 846-863.	5.6	110
9	Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for New-Onset Polyarticular Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 1063-1072.	3.4	101
10	The temporomandibular joint in juvenile idiopathic arthritis: frequently used and frequently arthritic. Pediatric Rheumatology, 2009, 7, 11.	2.1	99
11	Disease-modifying Antirheumatic Drug Use in the Treatment of Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the CARRA Registry. Journal of Rheumatology, 2012, 39, 1867-1874.	2.0	76
12	Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology, 2009, 48, 972-977.	1.9	68
13	Clinically Inactive Disease in a Cohort of Children with New-onset Polyarticular Juvenile Idiopathic Arthritis Treated with Early Aggressive Therapy: Time to Achievement, Total Duration, and Predictors. Journal of Rheumatology, 2014, 41, 1163-1170.	2.0	61
14	Health-Related Quality of Life, Physical Function, Fatigue, and Disease Activity in Children with Established Polyarticular Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 1330-1336.	2.0	58
15	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis and Rheumatology, 2019, 71, 864-877.	5.6	57
16	Intraarticular corticosteroid injections of the temporomandibular joint in juvenile idiopathic arthritis. Journal of Rheumatology, 2008, 35, 1157-64.	2.0	55
17	Heterotopic Ossification of the Temporomandibular Joint in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2011, 38, 1423-1428.	2.0	41
18	Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. Pediatric Rheumatology, 2017, 15, 23.	2.1	41

#	ARTICLE	IF	CITATIONS
19	Race, Ethnicity, and Disease Outcomes in Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. <i>Journal of Rheumatology</i> , 2013, 40, 936-942.	2.0	40
20	The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. <i>Arthritis and Rheumatology</i> , 2018, 70, 669-678.	5.6	40
21	Extension Study of Participants from the Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2459-2465.	2.0	35
22	Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature. <i>Paediatric Drugs</i> , 2019, 21, 469-492.	3.1	35
23	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. <i>Journal of Rheumatology</i> , 2019, 46, 1006-1013.	2.0	34
24	Disease activity and fatigue in juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 391-397.	3.4	33
25	Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score—Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1966-1975.	5.6	33
26	American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1. <i>Arthritis and Rheumatology</i> , 2020, 72, 1809-1819.	5.6	27
27	Daily Sleep Patterns, Sleep Quality, and Sleep Hygiene Among Parent-Child Dyads of Young Children Newly Diagnosed With Juvenile Idiopathic Arthritis and Typically Developing Children. <i>Journal of Pediatric Psychology</i> , 2016, 41, 651-660.	2.1	23
28	Identifying clinically meaningful severity categories for PROMIS pediatric measures of anxiety, mobility, fatigue, and depressive symptoms in juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus. <i>Quality of Life Research</i> , 2020, 29, 2573-2584.	3.1	22
29	Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease. <i>Arthritis Care and Research</i> , 2010, 62, 1095-1102.	3.4	21
30	Congruence between polysomnography obstructive sleep apnea and the pediatric sleep questionnaire: fatigue and health-related quality of life in juvenile idiopathic arthritis. <i>Quality of Life Research</i> , 2017, 26, 779-788.	3.1	21
31	Adding patient-reported outcomes to a multisite registry to quantify quality of life and experiences of disease and treatment for youth with juvenile idiopathic arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, .	1.9	20
32	Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. <i>Arthritis and Rheumatology</i> , 2021, 73, 1898-1909.	5.6	19
33	Oral health and plaque microbial profile in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2019, 17, 81.	2.1	18
34	Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1910-1920.	5.6	18
35	Making Decisions About Stopping Medicines for Well-Controlled Juvenile Idiopathic Arthritis: A Mixed-Methods Study of Patients and Caregivers. <i>Arthritis Care and Research</i> , 2021, 73, 374-385.	3.4	17
36	Sleep Disturbances and Behavior Problems in Children With and Without Arthritis. <i>Journal of Pediatric Nursing</i> , 2014, 29, 321-328.	1.5	16

#	ARTICLE	IF	CITATIONS
37	Management of temporomandibular joint arthritis in adult rheumatology practices: a survey of adult rheumatologists. <i>Pediatric Rheumatology</i> , 2012, 10, 26.	2.1	13
38	Sleep Fragmentation and Biomarkers in Juvenile Idiopathic Arthritis. <i>Biological Research for Nursing</i> , 2016, 18, 299-306.	1.9	13
39	The central nervous system manifestations of localized craniofacial scleroderma: a study of 10 cases and literature review. <i>Pediatric Radiology</i> , 2018, 48, 1642-1654.	2.0	13
40	Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. <i>Rheumatology International</i> , 2021, 41, 1755-1761.	3.0	12
41	Methotrexate and Injectable Tumor Necrosis Factor- $\alpha$ Inhibitor Adherence and Persistence in Children with Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2013, 40, 80-86.	2.0	11
42	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1884-1888.	2.0	11
43	Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Journal of Rheumatology</i> , 2021, 48, 1322-1329.	2.0	10
44	A retrospective study: Impact of consensus treatment plans on systemic therapy of pediatric morphea. <i>Pediatric Dermatology</i> , 2020, 37, 278-283.	0.9	9
45	Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study. <i>Journal of Rheumatology</i> , 2021, 48, 114-122.	2.0	9
46	American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2. <i>Arthritis and Rheumatology</i> , 2021, 73, e46-e59.	5.6	9
47	Novel Method to Collect Medication Adverse Events in Juvenile Arthritis: Results From the Childhood Arthritis and Rheumatology Research Alliance Enhanced Drug Safety Surveillance Project. <i>Arthritis Care and Research</i> , 2015, 67, 529-537.	3.4	8
48	Sleep Disturbances and Neurobehavioral Performance in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 361-367.	2.0	8
49	The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 35-42.	3.0	8
50	Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1976-1984.	5.6	8
51	A7: Initial Assessment of Multi-Biomarker Disease Activity Assay in JIA. <i>Arthritis and Rheumatology</i> , 2014, 66, S10.	5.6	6
52	Cutaneous polyarteritis nodosa in pediatric patients successfully treated with TNF- $\alpha$ inhibitor and methotrexate: Case series and literature review. <i>Pediatric Dermatology</i> , 2019, 36, 932-935.	0.9	4
53	FRI0556: A Multi-Biomarker Disease Activity Blood Test in Patients with Juvenile Idiopathic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 587.3-588.	0.9	0
54	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 1040-1041.	5.6	0

#	ARTICLE	IF	CITATIONS
55	The importance of rigorous methods in observational comparative effectiveness studies of rare diseases: comment on the article by Ruperto et al. Arthritis and Rheumatology, 2022, 74, 912-913.	5.6	0